ArticleNPJ breast cancer2022

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.

Luca Gianni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.